3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Nivolumab
3
fludarabine
2
Ipilimumab
2
tipifarnib
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
pembrolizumab
1
iso-sulfan blue
1
fludarabine phosphate
1
dostarlimab
1
bempegaldesleukin
1
Stem Cell Transplantation
1
Sirolimus
1
Mesna
1
Melphalan
1
Mass Spectrometry
1
LY2940680
1
Immunologic Techniques
1
Cyclophosphamide
1
Cryotherapy
1
Cryosurgery
1
Chromatography, High Pressure Liquid
1
CTLA-4 Antigen
1
Busulfan
1
BI 2536
1
Alemtuzumab
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts